The state of the art of bispecific antibodies for treating human malignancies

Bispecific antibodies (bsAb) that target two independent epitopes or antigens have been extensively explored in translational and clinical studies since they were first developed in the 1960s. Many bsAbs are being tested in clinical trials for treating a variety of diseases, mostly cancer. Here, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Shuhang, Chen, Kun, Lei, Qi, Ma, Peiwen, Yuan, Andy Qingan, Zhao, Yong, Jiang, Youwei, Fang, Hong, Xing, Shujun, Fang, Yuan, Jiang, Ning, Miao, Huilei, Zhang, Minghui, Sun, Shujun, Yu, Zicheng, Tao, Wei, Zhu, Qi, Nie, Yingjie, Li, Ning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422067/
https://www.ncbi.nlm.nih.gov/pubmed/34431224
http://dx.doi.org/10.15252/emmm.202114291

Ejemplares similares

Ejemplares similares